Legal Medicine Unit, 125694ASUR Marche, Macerata, Italy.
Neurological Unit, 125694ASUR Marche, Macerata, Italy.
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221128534. doi: 10.1177/03946320221128534.
In the current international scientific panorama, rare cases of venous thrombotic complications following mRNA vaccine administration have been reported, consisting mainly of cerebral sinus thromboses and acute venous thromboembolism. The present paper describes the case of a 75-year-old woman in good health who developed cerebral venous thrombosis, deep venous thrombosis, and bilateral pulmonary emboli after receiving a second dose of Pfizer-BioNTech COVID-19 vaccine. A series of laboratory tests performed during hospitalization yielded interesting results, allowing us to exclude thrombophilic risk factors and to certify the absence of thrombocytopenia in the patient. Although COVID-19 vaccination is the most important tool in stopping the pandemic, pharmacovigilance is crucial for detecting potential multisystem thrombotic events, even for mRNA vaccines.
在当前的国际科学领域,有报道称在接种 mRNA 疫苗后会出现静脉血栓并发症的罕见病例,主要包括脑窦血栓形成和急性静脉血栓栓塞。本文描述了一例健康状况良好的 75 岁女性,在接种第二剂辉瑞-生物科技公司的 COVID-19 疫苗后发生了脑静脉血栓、深静脉血栓和双侧肺栓塞。住院期间进行的一系列实验室检查结果有趣,排除了血栓形成的危险因素,并证明了患者没有血小板减少症。虽然 COVID-19 疫苗接种是阻止大流行的最重要工具,但药物警戒对于检测潜在的多系统血栓形成事件至关重要,即使是对于 mRNA 疫苗也是如此。